Ivelion recruits patients for Phase II, III, and IV trials. We read your protocol’s indication and every inclusion and exclusion criterion, then check them against documented patient data: in university clinics, in outpatient practices, and in what patients share with us from home. Every channel runs through the same filter, so your sites only see patients who match.
We take your protocol apart: indication, inclusion, exclusion. Then we run it as a query inside the clinic’s own systems, where the records already are. Every match traces back to a line in a patient’s record.
Built for the trials where recruitment decides the timeline, from first efficacy signals to post-approval evidence.
Every match starts from the full protocol: the indication first, then every single inclusion and exclusion criterion. All of them, before a name comes back.
Diagnoses and lab values, but also doctor’s letters and free-text notes. The criteria that decide eligibility often live outside the coded fields.
The search runs inside the clinic’s own systems, federated, so the records never leave the building. It reads structured and unstructured data alike: diagnoses, lab values, and the doctor’s letters in between. Every partner clinic is also a study center, so nobody has to be referred elsewhere to enroll.
Two ways in, one network. Posters in the waiting room invite patients to pre-qualify through Trial Screener, our chatbot, where they enter their information and upload documents like doctor’s letters. In parallel, we match against the practices’ own databases.
Social campaigns cast a deliberately wide net, and none of what they catch reaches your sites unfiltered. Every lead runs through the same chatbot first. Reach, without the noise.
Most campaigns hand their leads straight to the sites. The result is well documented: across therapeutic areas, more than a third of the candidates screened at a site fail there. In CNS trials, it’s worse still. Sites lose weeks of coordinator time to patients who were never eligible.
We route every campaign lead through Trial Screener first. Patients answer the questions behind your criteria, upload documents where they help, and find out early whether the study is worth a visit, before a site spends a single minute on them.
Only matching patients are forwarded. Your coordinators spend their time on the people who could actually enroll.
Source: Tufts Center for the Study of Drug Development, 76 Phase II and III trials across 7,085 sites, 2016–2019. Across all therapeutic areas: 36.3%.
No patient data moves without an explicit opt-in. Ever.
Data minimization and a full audit trail, built in from day one.
Processed and stored exclusively within the European Union.
Encrypted in transit and at rest, with every role seeing only what it needs.
Bring one protocol. We’ll show you how we find its patients, and what the funnel keeps away from your sites. Your first feasibility answer follows within one business day.